It refers to retatrutide, a tripleagonist weightloss medication that activates GLP1, GIP, and glucagon receptors. Early clinical trials show unprecedented weightloss results, often greater than currently approved GLP1 and dualagonist drugs, along with improvements in liver fat and metabolic markers. As research advances and more data become available, medically supervised programs will continue to evaluate where TRIPLEagonist medications fit among GLP1 drugs, dualagonists, peptides, and other tools for sustainable metabolic health
This concern applies equally to tirzepatide and liraglutide
Home/ Fat Loss Peptides Australia Fat Loss Peptides Australia Compare metabolic research peptides in Australia, including Retatrutide, Tirzepatide, Semaglutide, starter kits, value bundles, cutting stacks, and 120-unit precision pen systems
In the 18-week study, treatment with linagliptin 5 mg once daily provided statistically significant improvements from baseline in A1C and FPG compared with placebo